For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a genuine change. These novel therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the impact of the condition . Individuals are now experiencing positive ou… Read More